Some of the most exciting innovation in clinical medicine is occurring at the convergence of medicine and technology. At Intarcia, this is our 'sweet spot.' In Research & Development, our technology and drug development expertise is our key competitive advantage.
A Better Life Thanks to a Tiny Stick
Better outcomes that require daily management of chronic diseases or conditions may soon come in a tiny stick. This is demonstrated by our ability to stabilize therapeutic proteins, peptides and antibody fragments, and to deliver them in a constant and consistent manner over an extended period of time via our unique and proprietary subcutaneous drug-delivery system. It promises to be a game-changing way to control major diseases and conditions that seriously affect the health and well-being of many millions of people around the world.
Gaining better control of type 2 diabetes and obesity are two of our Company’s first and second targets respectively in our pipeline. Both have become public health mandates as these conditions have reached epidemic proportion in many developed countries.
Our most advanced product candidate is ITCA 650 for the treatment of type 2 diabetes. ITCA 650 is currently in a global phase 3 clinical trial program called FREEDOM. Our first interim phase 3 data in type 2 diabetes presented at the JP Morgan Healthcare Conference in January this year gave us an exciting glimpse of the significant potential we have to make a difference for patients, payors and providers alike. Much more data on this trial and our FREEDOM phase 3 program will be announced at major medical meetings throughout the rest of 2014 and 2015. Learn more about ITCA 650
Intarcia’s lead product candidate, ITCA 650 is being developed for the treatment of type 2 diabetes and employs Intarcia’s proprietary technology platform involving a matchstick-size, miniature osmotic pump that is inserted sub-dermally to provide continuous and consistent drug therapy.
Type 2 diabetes is the most common form of diabetes, and is triggered by a combination of risk factors that include older age, obesity, family history, having diabetes while pregnant, a sedentary lifestyle and race/ethnicity.2
Currently, 1 in 10 Americans have type 2 diabetes and 25 percent of them do not even know it. According to a 2010 report from the Centers for Disease Control and Prevention (CDC), 1 in 3 people in the U.S. will have type 2 diabetes by 2050 if current trends continue. As a result of the increasing prevalence of the disease, diabetes alone could account for about one-tenth of the nation's healthcare billsapproximately $500 billion annually.3